Integra LifeSciences IART Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$516.47M— | —— | $67.74M-62.5% | $180.55M+6.8% | ||
| $151.83M+7.8% | $140.89M+14.1% | $123.51M+4.4% | $118.3M-1.3% | ||
| $18.58M-23.8% | $24.38M+21.0% | $20.14M-27.3% | $27.73M-23.4% | ||
| -$66.26M-220% | -$20.73M-74.4% | -$11.89M-159% | -$4.59M— | ||
| —— | $0— | $0-100% | $644K-98.5% | ||
| $485K— | —— | —— | $33.91M— | ||
| $46.76M+56.4% | $29.89M-50.0% | $59.77M+105% | $29.12M+642% | ||
| $26.72M— | —— | -$22.14M-228% | $17.34M-48.8% | ||
| —— | —— | -$2.65M+69.2% | -$8.61M-141% | ||
| -$17.16M-18,347% | -$93K— | —— | —— | ||
| $3.4M-12.5% | $3.89M— | —— | $4.27M+15,164% | ||
| -$21.33M-268% | -$5.79M-145% | $12.89M+163% | -$20.3M-839% | ||
| $50.38M-61.1% | $129.38M-7.6% | $139.96M-47.1% | $264.47M-15.4% | ||
| $81.44M-22.0% | $104.42M+56.2% | $66.87M+57.9% | $42.34M-11.8% | ||
| —— | —— | $32.69M— | $0— | ||
| -$108.06M+72.3% | -$390.81M-315% | -$94.18M— | —— | ||
| $2.7M-23.2% | $3.51M-40.1% | $5.86M-76.2% | $24.62M+413% | ||
| —— | —— | —— | $0— | ||
| —— | —— | -$229.93M+8.7% | -$251.95M— | ||
| $18.82M+391% | -$6.46M-258% | $4.1M— | —— | ||
| —— | —— | —— | —— | ||
| $5.61M+0.2% | $5.59M-9.3% | $6.16M-9.9% | $6.85M-2.6% | ||
| -$21.33M-268% | -$5.79M-145% | $12.89M+163% | -$20.3M-839% | ||
| -$17.16M-18,347% | -$93K— | —— | —— | ||
| -$3.34M-218% | $2.84M-67.6% | $8.77M+302% | $2.18M— | ||
| —— | —— | -$2.65M+69.2% | -$8.61M-141% | ||
| $1.3M-84.6% | $8.45M— | $0— | $0— | ||
| —— | —— | —— | —— | ||
| $151.83M+7.8% | $140.89M+14.1% | $123.51M+4.4% | $118.3M-1.3% | ||
| —— | —— | —— | —— | ||
| $94.91M-49.3% | $187.13M+69.2% | $110.6M-25.5% | $148.55M+18.4% | ||
| $3.4M-12.5% | $3.89M— | —— | $4.27M+15,164% | ||
| —— | —— | —— | $0— | ||
| $720.7M+48.1% | $486.5M+195% | $165.1M+305% | $40.75M+59.8% | ||
| —— | —— | $73.09M-67.1% | $222.13M-16.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Integra LifeSciences generate?
- Integra LifeSciences (IART) generated $71.4M in operating cash flow over the trailing twelve months.
- What is Integra LifeSciences's free cash flow?
- After $67.4M of capital expenditures, Integra LifeSciences's free cash flow was -$61.8M over the trailing twelve months, down 193.2% year over year.
- Where does Integra LifeSciences's cash flow data come from?
- Every line is extracted from Integra LifeSciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
